198 related articles for article (PubMed ID: 30655498)
1. Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study.
Lladó L; González-Castillo A; Fabregat J; Baliellas C; Ramos E; González-Vilatarsana E; Busquets J; Xiol X
Ann Transplant; 2019 Jan; 24():36-44. PubMed ID: 30655498
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study.
Trunečka P; Klempnauer J; Bechstein WO; Pirenne J; Bennet W; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Kazeem G; Tisone G
Ann Transplant; 2019 Jun; 24():319-327. PubMed ID: 31160549
[TBL] [Abstract][Full Text] [Related]
4. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
Rummo OO; Carmellini M; Rostaing L; Oberbauer R; Christiaans MH; Mousson C; Langer RM; Citterio F; Charpentier B; Brown M; Kazeem G; Lehner F;
Transpl Int; 2017 Jan; 30(1):83-95. PubMed ID: 27754567
[TBL] [Abstract][Full Text] [Related]
5. Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study.
TruneČka P; Klempnauer J; Bechstein WO; Pirenne J; Friman S; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Tisone G;
Am J Transplant; 2015 Jul; 15(7):1843-54. PubMed ID: 25707487
[TBL] [Abstract][Full Text] [Related]
6. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
Wakasugi N; Uchida H; Uno S
Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
8. Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients.
Rummo O; Carmellini M; Kamar N; Durrbach A; Mousson C; Caputo F; Mathe Z; Christiaans MHL; Kuypers DRJ; Klempnauer J; Anaokar S; Hurst M; Kazeem G; Undre N; Lehner F
Transpl Int; 2020 Feb; 33(2):161-173. PubMed ID: 31536654
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
11. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study.
Neuberger JM; Mamelok RD; Neuhaus P; Pirenne J; Samuel D; Isoniemi H; Rostaing L; Rimola A; Marshall S; Mayer AD;
Am J Transplant; 2009 Feb; 9(2):327-36. PubMed ID: 19120077
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials.
Krämer BK; Albano L; Banas B; Charpentier B; Bäckman L; Tedesco-Silva H; Lehner F; Mondragón-Ramírez GA; Glyda M; Cassuto-Viguier E; Viklický O; Mourad G; Rigotti P; Schleibner S; Kamar N
Transplant Proc; 2017 Nov; 49(9):2040-2049. PubMed ID: 29149958
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.
Yoshida EM; Marotta PJ; Greig PD; Kneteman NM; Marleau D; Cantarovich M; Peltekian KM; Lilly LB; Scudamore CH; Bain VG; Wall WJ; Roy A; Balshaw RF; Barkun JS
Liver Transpl; 2005 Sep; 11(9):1064-72. PubMed ID: 16123958
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
Welberry Smith MP; Cherukuri A; Newstead CG; Lewington AJ; Ahmad N; Menon K; Pollard SG; Prasad P; Tibble S; Giddings E; Baker RJ
Transplantation; 2013 Dec; 96(12):1082-8. PubMed ID: 24056618
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Open-Label, Phase IV, Korean Study of Kidney Transplant Patients Converting From Cyclosporine to Prolonged-Release Tacrolimus Plus Standard- or Reduced-Dose Corticosteroids.
Baek CH; Kim CD; Lee DR; Kim YH; Yang J; Kim BS; Lee JS; Han SY; Kim SW; Lee S; Lee KW; Kong JM; Shin BC; Lee SH; Chae DW; Kwon YJ; Jiang H; Lee H; Park SK
Transplant Proc; 2019 Apr; 51(3):749-760. PubMed ID: 30979460
[TBL] [Abstract][Full Text] [Related]
16. One-year results of basiliximab induction and tacrolimus associated with sequential steroid and MMF treatment in pediatric kidney transplant recipient.
Montini G; Murer L; Ghio L; Pietrobon B; Ginevri F; Ferraresso M; Cardillo M; Scalamogna M; Perfumo F; Edefonti A; Zanon GF; Zacchello G
Transpl Int; 2005 Jan; 18(1):36-42. PubMed ID: 15612981
[TBL] [Abstract][Full Text] [Related]
17. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
[TBL] [Abstract][Full Text] [Related]
18. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
[TBL] [Abstract][Full Text] [Related]
19. Once-daily, prolonged-release tacrolimus vs twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: A Phase 4, randomized, open-label, comparative, single-center study.
Shin MH; Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Yun YI; Kim WJ; Kang WH; Kim SH; Jiang H; Lee S; Tak EY
Clin Transplant; 2018 Sep; 32(9):e13376. PubMed ID: 30098071
[TBL] [Abstract][Full Text] [Related]
20. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.
Hao JC; Wang WT; Yan LN; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
World J Gastroenterol; 2014 Aug; 20(32):11356-62. PubMed ID: 25170222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
